# A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

> **NCT06674577** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Vera Therapeutics, Inc.** · enrollment: 476 (estimated)

## Conditions studied

- IgA Nephropathy (IgAN)
- Renal and Urinary Disorders
- Berger Disease

## Interventions

- **DRUG:** Atacicept 150 mg

## Key facts

- **NCT ID:** NCT06674577
- **Lead sponsor:** Vera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-12-01
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 476 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674577, "A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06674577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*